Answers are grounded in this paper and cite their sources.
A series of 3-piperidyl-amino-l,2,4-triazin-6-yl-phenol analogs is described as inhibitors of NLRP3. NLR proteins are involved in the immune system. The activated NLRP3 protein assembles with other proteins into inflammasomes leading to downstream proteolytic events including the formation of proinflammatory cytokines such as IL-1B and IL 18. Inhibition of NLRP3 represents a potential treatment for multiple inflammatory diseases including Alzheimer’s disease, Parkinson’s disease nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), metabolic dysfunction-associated Steatohepatitis (MASH), and multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Gérard Rossé (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: